Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $219.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 32.19% year-over-year to $219.7 million, compared with a TTM value of $219.7 million through Dec 2025, up 32.19%, and an annual FY2025 reading of $219.7 million, up 32.19% over the prior year.
  • Other Non-Current Liabilities was $219.7 million for Q4 2025 at Neurocrine Biosciences, up from $195.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $219.7 million in Q4 2025 and bottomed at $8.3 million in Q3 2021.
  • Average Other Non-Current Liabilities over 4 years is $104.9 million, with a median of $78.6 million recorded in 2023.
  • Peak annual rise in Other Non-Current Liabilities hit 93.02% in 2021, while the deepest fall reached 1.39% in 2021.
  • Year by year, Other Non-Current Liabilities stood at $8.3 million in 2021, then soared by 726.51% to $68.6 million in 2023, then surged by 142.27% to $166.2 million in 2024, then surged by 32.19% to $219.7 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for NBIX at $219.7 million in Q4 2025, $195.7 million in Q3 2025, and $210.1 million in Q2 2025.